| Cancer stemness, intratumoral heterogeneity, and immune response across cancers | Proceedings of the National Academy of Sciences of the United States of America | 2019 | 164 |
| Changes in colorectal cancer incidence in seven high-income countries: a population-based study | The Lancet Gastroenterology and Hepatology | 2019 | 132 |
| Circulating biomarkers for early detection and clinical management of colorectal cancer | Molecular Aspects of Medicine | 2019 | 115 |
| Immune Thrombocytopenia | New England Journal of Medicine | 2019 | 113 |
| Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial | Lancet, The | 2019 | 85 |
| Connexins in cancer: bridging the gap to the clinic | Oncogene | 2019 | 79 |
| EPID-25. HOW MANY PATIENTS IN A REAL WORLD GLIOBLASTOMA POPULATION MEET ELIGIBILITY CRITERIA IN CLINICAL TRIALS? | Neuro-Oncology | 2019 | 78 |
| Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer | Annals of Oncology | 2019 | 70 |
| Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity | European Urology | 2019 | 59 |
| Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study | Lancet Oncology, The | 2019 | 57 |
| An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment | Nature Communications | 2019 | 55 |
| TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma | Cancer Immunology Research | 2019 | 49 |
| Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial | Ecological Management and Restoration | 2019 | 45 |
| Effects and moderators of exercise on muscle strength, muscle function and aerobic fitness in patients with cancer: a meta-analysis of individual patient data | British Journal of Sports Medicine | 2019 | 43 |
| Combination therapies with HSP90 inhibitors against colorectal cancer | Biochimica Et Biophysica Acta: Reviews on Cancer | 2019 | 40 |
| Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy | Annals of Oncology | 2019 | 40 |
| Pazopanib in relapsed osteosarcoma patients: report on 15 cases | Acta Oncológica | 2019 | 37 |
| International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV | Head and Neck | 2019 | 36 |
| Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy | Npj Breast Cancer | 2019 | 35 |
| DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies | International Journal of Molecular Sciences | 2019 | 34 |
| Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy | Blood | 2019 | 33 |
| Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) | European Journal of Cancer | 2019 | 32 |
| Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion | Blood Advances | 2019 | 32 |
| Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer | Translational Oncology | 2019 | 30 |
| Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group | Lancet Oncology, The | 2019 | 30 |
